@article{df133e0c7c804146a48da1f896110f09,
title = "Quality prescribing in early psychosis: key pharmacotherapy principles",
abstract = "Objective: To present a practical, easy-to-implement clinical framework designed to support evidence-based quality prescribing for people with early psychosis. Method: Identification and explanation of key principles relating to evidence-based pharmacotherapy for people with early psychosis. These were derived from the literature, practice guidelines and clinical experience. Results: Key principles include (1) medication choice informed by adverse effects; (2) metabolic monitoring at baseline and at regular intervals; (3) comprehensive and regular medication risk–benefit assessment and psychoeducation; (4) early consideration of long-acting injectable formulations (preferably driven by informed patient choice); (5) identification and treatment of comorbid mood disorders and (6) early consideration of clozapine when treatment refractory criteria are met. Conclusions: Current prescribing practices do not align with the well-established evidence for quality pharmacotherapy in early psychosis. Adopting evidence-based prescribing practices for people with early psychosis will improve outcomes.",
keywords = "antipsychotic medications, early psychosis, maintenance treatment, prescribing practices",
author = "Scott, {James G.} and Gemma McKeon and Eva Malacova and Jackie Curtis and Bjorn Burgher and Iain Macmillan and Andrew Thompson and Parker, {Stephen D.}",
note = "Funding Information: Employers of JGS (QIMR Berghofer Medical Research Institute and The University of Queensland) have received honoraria from Lundbeck, Janssen Cilag, Otsuka and Servier for his speaking at educational events and/ or advisory board participation. IM has received an honorarium from Otsuka Australia Pharmaceutical Pty Ltd for advisory board participation. SDP has received an honorarium and a Janssen Medical Education Grant from Johnson and Johnson. BB has received honorarium from Lundbeck for speaking at educational events. AT has received honoraria and support for meetings from Janssen Cilag, Servier, Eli Lilly and Otsuka Pharmaceuticals and has been an investigator on an unrestricted investigator-initiated trial funded by Janssen-Cilag. AT has also previously held a Pfizer Neurosciences Research Grant. JC has received honoraria from Janssen Cilag and Otsuka for speaking at educational events. The authors alone are responsible for the content and writing of this paper. Publisher Copyright: {\textcopyright} The Royal Australian and New Zealand College of Psychiatrists 2021.",
year = "2022",
month = jun,
doi = "10.1177/10398562211054656",
language = "English",
volume = "30",
pages = "341--345",
journal = "Australasian Psychiatry",
issn = "1039-8562",
publisher = "SAGE Publications Ltd",
number = "3",
}
